From: [redacted]@mscbs.es
To: EU NITAG COLLABORATION; [redacted]
Cc: [redacted]@mscbs.es
Subject: RE: FOR CONTRIBUTION AND INFO - Upcoming NITAG collaboration meeting planned on 1 July 2021: Adaptations of COVID-19 vaccination programmes: new evidence and country experiences
Date: 29 June 2021 15:24:09
Attachments: image001.gif
image002.png
image003.png
image004.png
image005.png

Dear colleagues,
Please find below the answers to the formulated questions.

Kind regards,

[redacted]
DIRECTORATE GENERAL OF PUBLIC HEALTH
Ministry of Health
Paseo del Prado, 18-20. Office [redacted]
28071 Madrid. Spain.

Telephone: (+34) [redacted]
Fax: (+34) [redacted]
Email: [redacted]@mscbs.es

De: EU NITAG COLLABORATION [mailto:EU.NITAG.COLLABORATION@ecdc.europa.eu]
Enviado el: lunes, 28 de junio de 2021 16:30
Para: [redacted]@isciii.es; [redacted]@mscbs.es; [redacted]
CC: [redacted]
Asunto: RE: FOR CONTRIBUTION AND INFO - Upcoming NITAG collaboration meeting planned on 1 July 2021: Adaptations of COVID-19 vaccination programmes: new evidence and country experiences

Dear colleagues,

In preparation for the upcoming NITAGs webinar on the **1st of July**, this is a gentle reminder to provide your feedback and answers to the questions shared last week on the 23rd of June (attached email; questions copied below), possibly by tomorrow 29 June (end of business).
If you have already provided your feedback, we really appreciate your timely contribution and please disregard this message.

Kind regards

[redacted]
VPI team

Questions – One reply by Member States (please select or colour shade the appropriate answer)

Topic 1: Third dose of vaccine (for vaccines given in a two-dose schedule) or a second dose of vaccine (for the vaccine in a single dose schedule)

Question 1: Is your country **currently** recommending a third dose of vaccine (for vaccines given in a two-dose schedule) or a second dose of vaccine (for the vaccine in a single dose schedule)?

- Yes
- Yes, but only for those in risk groups, such as immunocompromised individuals (please specify)
- No

Please feel free to add comments to complement your answer or provide a link to national recommendations: Not at this moment, but we are considering a third dose in certain risk groups, such as immunocompromised subjects

Question 2: Is your country NITAG **discussing recommendation for an additional dose** (3rd or 2nd depending on the vaccine used) in the "coming months"?

- No
  - If no, what information would be required to facilitate/support your discussions? Information about the duration of effectiveness of complete immunization (is it different by age groups?), the adding effect of an additional dose (is it necessary to administer a complete dose or could it be enough with half dose, by age group?), impact of booster with specific vaccines formulated for specific SARS-CoV variants …
- Yes
  - If yes, is there any public information available?

Please feel free to add comments to complement your answer and detail the stage of discussion and evidence being assessed Even though the NITAG is not discussing it at this very moment, it is expected to be one task for the following weeks/months

Topic 2: Heterologous vaccination schedules

Question 3: Is your country **recommending a heterologous combination of vaccine doses** (so-called mix and match) (e.g. Vaxzevria first dose followed by Comirnaty for second dose)?

- Yes
  - If yes, please provide details on which vaccines and for any particular groups this is recommended for:

ECDC Logo

European Centre for Disease Prevention and Control (ECDC)
Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01
www.ecdc.europa.eu

  - Individuals younger than 60 years that received one dose of Vaxzevria are recommended to receive one dose of Comirnaty
- No
  - If no, what information would be required to facilitate/support your discussions?
- Under discussion

Please feel free to add comments to complement your answer or provide a link to national recommendations

Topic 3: Variants of concern

Question 4: Has there been any change in the vaccination strategy in light of the circulation of new variants of concern (in particular de new Delta variants)? (E.g., reducing the timing between dose one and dose two; adaption of priority groups; use of one vaccine product for certain target groups, prioritisation of geographical areas where new variants have been circulating etc…).

- Yes
  - If yes, what changes have been implemented?
- No
- Currently under discussion

A reduction in the interval on the Vaxzevria vaccine (currently between 10-12 weeks is under discussion. Comirnaty and Moderna vaccines are already administered at 3 and 4 week between doses

Please feel free to add comments to complement your answer or provide a link to national recommendations

---

From: EU NITAG COLLABORATION
Sent: 23 June 2021 11:14
To: [redacted]@mscbs.es; [redacted]@isciii.es; [redacted]@mscbs.es; [redacted]
Cc: EU NITAG COLLABORATION <xx.xxxxx.xxxxxxxxxxxx@xxxx.xxxxxx.xx>; [redacted]
Subject: FOR CONTRIBUTION AND INFO - Upcoming NITAG collaboration meeting planned on 1 July 2021: Adaptations of COVID-19 vaccination programmes: new evidence and country experiences

To: Members and Alternate of the EU/EEA NITAG Collaboration

Dear Colleagues -

Please find below information about an upcoming NITAG webinar for your information and contribution in building the content and discussions. we strive to ensure those meetings meet your need and contribute to discussions ongoing at national level.

Thanking you for your time to go through and reply directly to this email by Thursday 24th end of day if possible. In particular on your willingness to contribute as speakers.

Kind regards

[redacted]
ECDC EU/EEA NITAG secretariat
On behalf of the ECDC VPI team

Subject: Upcoming NITAG collaboration meeting on 1 July 2021

Proposed title: Adaptations of COVID-19 vaccination programmes: new evidence and country experiences

This email is intended to:

1. **Inform** you about an upcoming meeting of the EU/EEA NITAG collaboration which will take place on 1 July 2021 at 15.00h (Stockholm time; duration 2h). This is possibly going to be the last meeting before the summer break. Please bookmark your calendars. Formal invitation and agenda to be shared soon.

2. **Outline** planned topics for the meeting (see below) and ensure these are in-line with your current needs for decision-making.

3. **Ask if you can contribute as speakers** to this webinar by sharing status of discussions at national level on the proposed topics and your ongoing work.

4. **Reply to a few questions** for your kind attention (included at the end of this email) that will help us built the agenda and facilitate the discussion.

Proposed topics for the agenda:

The focus of the meeting is proposed to be on the following topics of current interest:

- **The "Delta variant"** - Adjustments needed to vaccination programmes to contain spread and limit public health impact. Presentation of the ECDC Threat Assessment Brief.

- **3rd COVID-19 dose** (or 2nd in some cases or for some vaccines) – status of discussion at national level. Population possibly targeted. Data needed to inform decisions on the administration of booster doses in the upcoming months .

- **"Mix and match" or heterologous vaccination schedules** – overview of latest available data on immunogenicity. Adoption and evidence from EU/EEA countries.

Would you please -

- **Indicate** if the proposed topics match your current needs or not. If not, which topics of interest would you propose?

- **Confirm** your availability to contribute to any of the proposed topics and share your country experience. Even an oral update would be informative (no need for slides).

- **Reply** to the 4 questions listed below and provide as much detail as can possibly be shared

Questions – One reply by Member States (please select or colour shade the appropriate answer)

Topic 1: Third dose of vaccine (for vaccines given in a two-dose schedule) or a second dose of vaccine (for the vaccine in a single dose schedule)

Question 1: Is your country **currently** recommending a third dose of vaccine (for vaccines given in a two-dose schedule) or a second dose of vaccine (for the vaccine in a single dose schedule)?

- Yes
- Yes, but only for those in risk groups, such as immunocompromised individuals (please specify)
- No

Please feel free to add comments to complement your answer or provide a link to national recommendations

Question 2: Is your country NITAG **discussing recommendation for an additional dose** (3rd or 2nd depending on the vaccine used) in the "coming months"?

- No
  - If no, what information would be required to facilitate/support your discussions?
- Yes
  - If yes, is there any public information available?

Please feel free to add comments to complement your answer and detail the stage of discussion and evidence being assessed

Topic 2: Heterologous vaccination schedules

Question 3: Is your country **recommending a heterologous combination of vaccine doses** (so-called mix and match) (e.g. Vaxzevria first dose followed by Comirnaty for second dose)?

- Yes
  - If yes, please provide details on which vaccines and for any particular groups this is recommended for:_____
- No
  - If no, what information would be required to facilitate/support your discussions?
- Under discussion

Please feel free to add comments to complement your answer or provide a link to national recommendations

Topic 3: Variants of concern

Question 4: Has there been any change in the vaccination strategy in light of the circulation of new variants of concern (in particular de new Delta variants)? (E.g., reducing the timing between dose one and dose two; adaption of priority groups; use of one vaccine product for certain target groups, prioritisation of geographical areas where new variants have been circulating etc…).

- Yes
  - If yes, what changes have been implemented?

- No

- Currently under discussion

Please feel free to add comments to complement your answer or provide a link to national recommendations